AVAX Technologies, Inc.

AVAX Technologies, Inc.

AVAX Technologies company is developing vaccines created by extracting a patient's own cancer cells and chemically treating them to induce an immune system response. The technology used to create the vaccines (called AC Vaccine) is licensed from Thomas Jefferson University. AVAX's lead vaccine candidate M-Vax is intended as a post-surgical treatment for late-stage melanoma, but the company is also developing vaccine candidates to fight ovarian cancer (O-Vax) and non-small cell lung cancer (L-Vax). The company also offers contract manufacturing services to other biotech and pharmaceutical companies.

Contact Details

Office Address

AVAX Technologies, Inc.
2000 Hamilton Street, Suite 204
Philadelphia, PA, USA 19130
Phone: (215) 241-9760
Fax: (215) 241-9684

Executives

Chairman

John K. A. Prendergast

President, CEO, and Director

François R. Martelet

Business Reviews for AVAX Technologies, Inc.

Related Companies